Advanced Biomed (NASDAQ:ADVB) Issues Earnings Results

Advanced Biomed (NASDAQ:ADVB) issued its earnings results on Tuesday. The company reported $0.44 EPS for the quarter, FiscalAI reports.

Advanced Biomed Stock Down 2.3%

NASDAQ ADVB traded down $0.12 on Tuesday, reaching $5.16. The company had a trading volume of 4,753 shares, compared to its average volume of 761,429. The stock has a market capitalization of $8.51 million, a P/E ratio of 1.07 and a beta of 0.01. The company’s fifty day moving average is $7.70 and its 200 day moving average is $6.46. Advanced Biomed has a 52-week low of $3.61 and a 52-week high of $24.23.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Advanced Biomed to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings cut shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Advanced Biomed Company Profile

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.